Advanced Therapies Integrates 2021 Track 2
NOVEL NETWORKS & FINANCE
Welcome and opening remarks
Finding the Funds
Are the existing approaches to financing ATMP developers fit for purpose; what should analysts really be looking for in an Advanced Therapy?
SARAH BRUCE-WHITE | Partnerships & Programme’s Lead | MedCity
JASON MELLAD | Chief Executive Officer | Start Codon
FABIO d’AGOSTINO | Venture Partner | Claris Ventures
ERIC HALIOUA | President & Chief Executive Officer | PDC*line Pharma
TIMOTHY NEWTON | Chief Executive Officer | Reflection Therapeutics
Evolving the relationship between developers, regulators, payers, providers and patients to speed ATMP development through to adoption. How healthy are the Technology Assessments for ATMPs, are they revealing the full value?
STEVE McCONCHIE | Chief Executive Officer | Aptus Clinical
FIONA THISTLETHWAITE | Medical Oncology Consultant | The Christie NHS Foundation Trust
BILL SHINGLETON | Department Director, Biology – Cell & Gene Therapy | Cytiva
STEPHEN LITTLE | Vice Chairman | Yourgene Health
ANTHONY WILSON | Consultant in Anaesthesia and Critical Care | Manchester University NHS Foundation Trust
CLARE HAGUE Therapy Area Market Access Leader for Hematology | Janssen (a Johnson & Johnson company)
Market forces or forcing the market
What are the current challenges and future opportunities for opening up the ATMP markets? MHRA, NICE and NHS England are working together can make the UK attractive, but there are lower number of patients in UK as opposed to Europe. So how attractive is the UK for investment? How can investors get quicker and better returns? Is there a divergence from MHRA and EMA?
NATHAN SIGWORTH | Co-founder and Chief Executive Officer | PharmaCCX
CAROLE LONGSON | Independent Senior Advisor | Life Science Policy, HTA and Market Access
ROUDIE SHAFIE | Director | OVID Health
ALASTAIR THONG | Founder | Selvedge Venture
GAVIN LEWIS | Vice President, Global Value and Access | Amgen (Europe) GmbH
Go with the (cash) flow
Investment and infrastructure have been put in place to rapidly translate ATMPs from concept to clinic. But are we doing enough?
SALLY ANN FORSYTH | Chief Executive Officer | Stevenage Bioscience Catalyst
DAN PEARCE | Vice President, European Manufacturing & Technical Operations | Adaptimmune
WILL ROHLEDER | Director | Reef Group
KASIA AVERALL | Head of Cluster Development | Cell and Gene Therapy Catapult
JENNY LAIRD | Vice President, Search & Evaluation Pain & Neurodegeneration | Eli Lilly and Company
MARY JONES | Deputy Director for Strategy, Investment and Manufacturing | Office for Life Sciences
Skills: The global gold rush
How can stakeholders come together to address cell and gene therapy’s global talent gap? Do we have the right skills and capabilities in place to identify and develop the next generation of ATMPs?
JAMES STRACHAN | Editor | The Cell + Gene Curator
SVEN KILI | Chief Executive Officer | Antion Biosciences
TONY KHOURY | Executive Vice President | Project Farma
BRUCE LEVINE | Founding Director | Clinical Cell and Vaccine Production Facility
TAMAS MASZTIS | Senior Director | Cell Therapy Supply Chain for Europe, Kite, a Gilead Company
CLAIRE THOMPSON | Chief Executive Officer | Agility Life Sciences